Important Information Regarding Vyzulta

Posted in Latest News on March 16, 2018.

During the March 9, 2018 Board of Optometry meeting, the board approved for addition to Rule 64B13-18.002 Formulary of Topical Ocular Pharmaceutical Agents, Vyzulta (latanoprostene bunod ophthalmic solution) 0.024%.

Important note, Vyzulta, at this time, cannot be prescribed by certified Optometrists in Florida until the rule has been approved. Once the rule has gone through the approval process, notice will be provided on this site, and at that time Vyzulta may be prescribed by certified optometrists.

 



More Latest News

Third Quarter Performance Report
June 14, 2022

Released for the
2021 – 2022 Fiscal Year Continue reading


Topical Ocular Pharmaceutical Agents added to Formulary
May 27, 2022

The Board of Optometry has added the following Topical Ocular Pharmaceutical Agents to the formulary… Continue reading